-
Targeting inflammation to prevent severe acute pancreatitis: NSAIDs are not the holy grail Dig. Liver Dis. (IF 4.5) Pub Date : 2024-03-11 Gabriele Capurso, Alberto Malesci
-
Association between low-dose aspirin and the risk of gastric cancer and adenoma according to a family history of gastric cancer Dig. Liver Dis. (IF 4.5) Pub Date : 2024-03-11 Yoon Suk Jung, Mai Thi Xuan Tran, Boyoung Park, Chang Mo Moon
This study aimed to evaluate the association between low-dose aspirin use and the risk of GC and gastric adenoma according to a family history of GC. We conducted a population-based study of 7,596,003 participants screened for GC between 2013 and 2014. Aspirin users and non-users were matched in a 1:1 ratio through propensity score matching (PSM). After PSM, 51,818 participants with a family history
-
Positive phosphatidyl-ethanol test in liver disease patients: You can't handle the truth! Dig. Liver Dis. (IF 4.5) Pub Date : 2024-03-11 Yaser Al-Salmay, Ashwani K. Singal
-
-
Position paper on transanal irrigation in chronic non-organic constipation Dig. Liver Dis. (IF 4.5) Pub Date : 2024-03-08 G. Bazzocchi, E.S. Corazziari, A. Staiano, G. Bassotti, M. Bellini, G. Chiarioni, L. D'Alba, E. Scarpato
The practice of recto-colonic water irrigation to treat constipation has been used since ancient times with different, uncontrolled, and variably performing methods which have been considered interchangeably all alike. The use of better-performing devices with a standardized methodology is relatively recent, and the term Trans Anal Irrigation (TAI) defines a methodology performed with devices able
-
Artificial Intelligence-assisted colonoscopy and colorectal cancer screening: Where are we going? Dig. Liver Dis. (IF 4.5) Pub Date : 2024-03-08 Marco Spadaccini, Joel Troya, Kareem Khalaf, Antonio Facciorusso, Roberta Maselli, Alexander Hann, Alessandro Repici
Colorectal cancer is a significant global health concern, necessitating effective screening strategies to reduce its incidence and mortality rates. Colonoscopy plays a crucial role in the detection and removal of colorectal neoplastic precursors. However, there are limitations and variations in the performance of endoscopists, leading to missed lesions and suboptimal outcomes. The emergence of artificial
-
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-03-02 Karoline Anisdahl, Sandre Svatun Lirhus, Asle W Medhus, Bjørn Moum, Hans Olav Melberg, Marte Lie Høivik
To determine real-world medical and surgical treatment patterns in elderly-onset inflammatory bowel disease in a nationwide cohort, and to investigate associations between frailty and treatment choices. Norwegian health registries were used to identify adult-onset (born 1950–1989) and elderly-onset (born 1910–1949) patients with Crohn's disease (CD) and ulcerative colitis (UC) diagnosed 2010–2017 (
-
You can't handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients Dig. Liver Dis. (IF 4.5) Pub Date : 2024-03-01 Kyle Scholten, Patrick Twohig, Kaeli Samson, Kevin Brittan, Alexandra Fiedler, Josh Warner, Tomoki Sempokuya, Anna Willet, Thoetchai(Bee) Peeraphatdit, Marco Olivera
Serum phosphatidylethanol (PEth) testing has emerged as a promising biomarker for assessing recent alcohol consumption, surpassing the limitations of self-reported data. Limited clinical data exists comparing PEth levels and patients' reported alcohol intake. Compare PEth testing results with self-reported alcohol intake and assesses variables associated with underreporting. Single-center retrospective
-
Aetiology and diagnostic utility of serum ascites albumin gradient in children with ascites Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-29 Srinivas Srinidhi Vadlapudi, Anshu Srivastava, Nidhi Saini, Moinak Sen Sarma, Ujjal Poddar, Surender Kumar Yachha
Ascites in children is multifactorial and serum ascites albumin gradient (SAAG) ≥1.1 helps differentiate portal hypertension (PHTN) related from non-PHTN ascites. We evaluated the aetiology and diagnostic accuracy of SAAG in children with ascites. Children with ascites were retrospectively evaluated. Etiological diagnosis was based on clinical presentation and investigations. All cases with ascitic
-
Characteristics of microbiomes of the saliva, duodenal bulb, and descending portion of superficial nonampullary duodenal epithelial tumors Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-26 Hiroyuki Shibata, Kenta Yamamoto, Takashi Hirose, Satoshi Furune, Naomi Kakushima, Kazuhiro Furukawa, Masanao Nakamura, Takashi Honda, Mitsuhiro Fujishiro, Hiroki Kawashima
Nonampullary duodenal epithelial tumors are rare, but their prevalence is increasing. Various gastrointestinal cancers have been associated with microbiomes. We evaluated the characteristics of the salivary and duodenal microbiomes of patients with nonampullary duodenal epithelial tumors. Saliva and biopsy samples from the duodenal bulb and descending portion were obtained from 15 patients with nonampullary
-
Gastric cancer screening in Western countries: A call to action Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-24 Fabio Farinati, Filippo Pelizzaro
Gastric cancer is a major cause of cancer-related death worldwide, despite the reduction in its incidence. The disease is still burdened with a poor prognosis, particularly in Western countries. The main risk factor is the infection by classified as a class I carcinogen by the IARC, and It is well-known that primary prevention of gastric cancer can be achieved with the eradication of the infection
-
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-24 R. Varnier, C. Toullec, S. Philonenko, A. Dupré, P. Artru, E. Hafliger, A. Drouillard, C. Torregrosa, S. Pernot, P. McLellan, T. Lecomte, V. Moulin, C. Lécaille, Y. Touchefeu, C. Locher, J. Taieb, C. Coutzac
Prior trials validated triplet chemotherapy (Tri-CT) with bevacizumab as first line treatment for metastatic colorectal cancer (mCRC) but real-world data are scarce and practices remain heterogeneous. To evaluate Tri-CT +/- bevacizumab efficacy and safety, and to identify factors influencing treatment decisions. The COLOTRIP retrospective study enrolled mCRC patients treated from 2014 to 2019 in 14
-
A deep learning model based on magnifying endoscopy with narrow-band imaging to evaluate intestinal metaplasia grading and OLGIM staging: A multicenter study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-23 Wenlu Niu, Leheng Liu, Zhixia Dong, Xiongzhu Bu, Fanghao Yao, Jing Wang, Xiaowan Wu, Congying Chen, Tiancheng Mao, Yulun Wu, Lin Yuan, Xinjian Wan, Hui Zhou
Patients with stage III or IV of operative link for gastric intestinal metaplasia assessment (OLGIM) are at a higher risk of gastric cancer (GC). We aimed to construct a deep learning (DL) model based on magnifying endoscopy with narrow-band imaging (ME-NBI) to evaluate OLGIM staging. This study included 4473 ME-NBI images obtained from 803 patients at three endoscopy centres. The endoscopic expert
-
Factors associated with gastric and duodenal neuroendocrine tumors: A multicenter case-control study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-18 Kwangwoo Nam, Su Youn Nam, Jun Chul Park, Young Sin Cho, Hyuk Soon Choi, Kyoungwon Jung, Seon-Young Park, Joon Hyun Cho, Hyonho Chun
The incidence of gastric and duodenal neuroendocrine tumors (GNET and DNET, respectively) is increasing, however associated factors of these diseases are not well known. Here, we investigated the factors associated with GNET and DNET. Patients with GNET and DNET presenting at eight tertiary referral centers between 2001 and 2020 were included and compared with healthy controls who underwent upper endoscopic
-
GCNT3 regulated MUC13 to promote the development of hepatocellular carcinoma through the GSK3β/β-catenin pathway Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-17 Qiu Kang, Wu Tingting, Dong Bingzi, Zou Hao, Xie Yuwei, Sun Chuandong, Zhu Chengzhan
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Extensive research is currently directed at identifying novel targets for its diagnosis and treatment. We investigated the biological functions and clinical significance of mucin-type N-acetylglucosaminyltransferase 3 (GCNT3) in HCC. Variations in the mRNA expression of GCNT3 were examined in normal and HCC tissues
-
Deficits in geriatric assessment are important in relation to fatigue in older patients with Inflammatory Bowel Disease Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-17 Anne B. Fons, Vera E.R. Asscher, Rogier J.L. Stuyt, A.Martine C. Baven-Pronk, Sander van der Marel, Rutger J. Jacobs, Simon P. Mooijaart, Piet Eikelenboom, Andrea E. van der Meulen-de Jong, Kees J. Kalisvaart, P.W. Jeroen Maljaars
No previous study has investigated fatigue in older patients with Inflammatory Bowel Disease (IBD). To describe the prevalence of fatigue in older patients and compare it to the prevalence in younger patients with IBD, and to determine factors associated with fatigue. A prospective, multicenter cohort study, including older- (≥ 65 years) and younger patients with IBD (18–64 years). A geriatric assessment
-
CLCA1 1 in cancer: A tumor suppressor or oncogene? Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-17 Qing Jia, Hua Shang, Baozhen Li, Min Li
-
Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-15 Stefan Schreiber, Geert D'Haens, Fraser Cummings, Peter M. Irving, Byong Duk Ye, Shomron Ben-Horin, Dong-Hyeon Kim, Ae Lee Jeong, Walter Reinisch
Pharmacokinetic non-inferiority of subcutaneous (SC) to intravenous (IV) CT-P13 maintenance therapy was demonstrated in a randomized trial (NCT02883452). This analysis evaluated longitudinal clinical outcomes with the two infliximab treatment strategies. Patients with Crohn's disease or ulcerative colitis received CT‑P13 IV loading doses (5 mg/kg; Week [W] 0 and W2) before randomization (1:1) to receive
-
-
Very early onset inflammatory bowel diseases: Is it the time to share and define a histopathological reporting scheme? Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-12 Paola Parente, Alessandro Vanoli, Matteo Fassan, Luca Mastracci, Federica Grillo
-
Author's reply: Assessing disease severity in inflammatory bowel disease – Can we reliably encompass the full disease burden? Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-12 Qiu Yun, Mao Ren
-
Can NPC1L1 inhibitors reduce the risk of biliary tract cancer? Evidence from a mendelian randomization study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-10 Hao Dong, Rong Chen, Jiafeng Wang, Ningli Chai, Enqiang Linghu
Oxysterols have been implicated in biliary tract cancer (BTC), and Niemann-Pick C1–like 1 (NPC1L1) has been associated with oxysterol uptake in biliary and intestinal cells. Thus, our study aims to investigate the potential causal link between genetically proxied NPC1L1 inhibitors and the risk of BTC. In this study, we employed two genetic instruments as proxies for NPC1L1 inhibitors, which included
-
The role of miRNA in IBS pathogenesis, diagnosis and therapy: The latest thought Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-10 Xiaoyu Zhang, Lei Shi, Chen Chen, Yuning Ma, Yuxia Ma
IBS is a prevalent clinical condition affecting bowel function. There is a restricted comprehension of its pathogenesis, an absence of particular diagnostic tools, and an insufficiency of efficient pharmacological remedies. MiRNAs are a highly conserved class of non-coding small molecule RNAs, with a length of 20–24 nucleotides. Research has shown the presence of a number of differentially expressed
-
Gastrointestinal bleeding by jejunal myoepithelial hamartoma Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-10 Dong-Ge Han, Niu Tan, Wei Liu
-
Acinar cell carcinoma of splenic heterotopic pancreas origin Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-10 Yajun Liang, Jun Zhang
-
A rare case of abdominal pain: Pneumatosis cystoids intestinalis Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-09 Wei Liu, Dong-Ge Han, Lin Cheng
-
Triple synchronous epigastric tumors: A rare case Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-09 Yongquan Yu, Minglei Wang, Jie Liu
-
Author's reply: ABCA8, a tumour suppressor in colorectal cancer Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-09 Kun Yang, Zheng Jiang
-
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-09 Benedetta Stefanini, Laura Bucci, Valentina Santi, Nicola Reggidori, Lorenzo Lani, Alessandro Granito, Filippo Pelizzaro, Giuseppe Cabibbo, Mariella Di Marco, Giorgia Ghittoni, Claudia Campani, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Edoardo G. Giannini, Elisabetta Biasini, Carlo Saitta, Donatella Magalotti, Angelo Sangiovanni, Maria Guarino, Antonio Gasbarrini, Gian Ludovico Rapaccini
The efficacy of systemic therapy for unresectable advanced hepatocellular carcinoma (aHCC) has not been proven in patients with Child-Pugh (C-P) B cirrhosis. Nevertheless, in real-world these patients are treated both with tyrosine kinase inhibitors (TKIs) and with metronomic capecitabine (MC). This study aimed to compare sorafenib and MC outcomes versus best supportive care (BSC) in C-P B patients
-
Association between dairy-rich dietary pattern and metabolic dysfunction-associated steatotic liver disease: Findings from the Korean Genome and Epidemiology Study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-08 Jong Hee Lee, Hye Sun Lee, Soyoung Jeon, Jun-Hyuk Lee, Yu-Jin Kwon
-
The learning curve for using intestinal ultrasonography Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-05 Cristina Bezzio, Simone Saibeni, Marta Vernero, Federica Furfaro, Michela Monteleone, Davide Ribaldone, Gionata Fiorino, Antony B. Friedman, Alessandro Armuzzi, Davide Scalvini, Giovanni Maconi
Intestinal ultrasonography (IUS) is challenging to learn. This prospective study examined how the accuracy of IUS increases with operator experience (“learning curve”) and if prior abdominal ultrasound experience facilitates the learning process. The study included two trainees with limited abdominal ultrasound experience (< 50 exams) and two with extensive experience (> 500 exams). Each trainee performed
-
Efficacy and safety of piecemeal submucosal tunneling endoscopic resection for giant esophageal leiomyoma Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-05 Authors Xin Li, En Liu, Xia Xie, Xue Peng, Xu-biao Nie, Jian-jun Li, Yong Gao, Lu Liu, Jian-ying Bai, Tong-chuan Wang, Chao-qiang Fan
Giant esophageal leiomyoma usually requires a thoracotomy or thoracoscopic surgery, which is more invasive than an endoscopic treatment. The purpose of this study is to evaluate the efficacy and safety of piecemeal submucosal tunneling endoscopic resection (P-STER) for giant leiomyoma originating from the muscularis propria (MP) layer of the esophagus. This is a retrospective study. Patients with giant
-
Role of the artificial intelligence in the management of T1 colorectal cancer Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-03 Katsuro Ichimasa, Shin-ei Kudo, Masashi Misawa, Yuki Takashina, Khay Guan Yeoh, Hideyuki Miyachi
Approximately 10% of submucosal invasive (T1) colorectal cancers demonstrate extraintestinal lymph node metastasis, necessitating surgical intervention with lymph node dissection. The ability to identify T1b (submucosal invasion depth ≥ 1000 µm) as a risk factor for lymph node metastasis via pre-treatment endoscopy is crucial in guiding treatment strategies. Accurately distinguishing T1b from T1a (submucosal
-
Unexpectedly low accuracy of GPT-4 in identifying common liver diseases from CT scan images Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-03 Yiwen Zhang, Liwei Wu, Yangang Wang, Bin Sheng, Yih Chung Tham, Hongwei Ji, Ying Chen, Linlin Ren, Hanyun Liu, Lili Xu
Abstract not available
-
Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-03 Fatima Rajab, Aleena Mujahid, Hadia Rajab, Abdullah Alvi
Abstract not available
-
Tofacitinib in ulcerative colitis –In the era of precision medicine’ Dig. Liver Dis. (IF 4.5) Pub Date : 2024-02-02 Sidharth Harindranath, Ankita Singh
Abstract not available
-
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD) Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-30 Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Incà, Marco Astegiano, Walter Fries, Monica Milla, Carolina Ciacci, Fernando Rizzello, Simone Saibeni, Rachele Ciccocioppo, Ambrogio Orlando, Fabrizio Bossa, Mariabeatrice Principi, Piero Vernia, Chiara Ricci, Maria L. Scribano, Giorgia Bodini, Dario Mazzucco, Gabrio Bassotti, Gabriele Riegler, Irene Zammarchi
Background The RIDART I study found a 13.6% prevalence of anemia in Italian patients with inflammatory bowel disease (IBD); most cases were due to iron-deficiency anemia (IDA). Aims To evaluate changes in hemoglobin concentration during a 24-week follow-up of anemic patients with IBD. Methods Follow-up laboratory and clinical data were obtained from RIDART I study patients with anemia. Factors affecting
-
Factors associated with corticosteroid use in Crohn's disease and ulcerative colitis patients in Israel: A multicenter cross-sectional study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-29 Revital Barkan, Leonid Shpoker, Rasha Abboud, Smadar Nafrin, Tal Ilsar, lani Ofri, Ayala Blau, Rachel Gingold-Belfer, Henit Yanai, Iris Dotan, Jacob E Ollech
Background We examined corticosteroid use among Israeli patients with Inflammatory Bowel Disease (IBD), focusing on demographic, disease-related, and psychosocial factors. The objective was to contribute to the development of strategies minimizing corticosteroid dependence and improving patient outcomes, given the adverse effects associated with prolonged corticosteroid use. Methods A comprehensive
-
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-27 M. Hupé, A. Streichenberger, P. Wils, N. Arab, M. Serrero, A. Amiot, A. Bozon, L. Vuitton, M. Fumery, R. Altwegg, M. Nachury, X. Hébuterne, C. Yzet, D. Coban, M. Dodel, M. Bazoge, B. Pereira, A. Buisson
Background Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited. Aims To evaluate infliximab effectiveness and its predictors in UC patients with prior exposure to subcutaneous (SC) anti-TNF agent. Methods In this multicenter retrospective study (8 centers), we included all consecutive UC patients with prior exposure to subcutaneous anti-TNF, starting infliximab
-
Assessing disease severity in inflammatory bowel disease - Can we reliably encompass the full burden of illness? Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-29 Akhilesh Swaminathan, Andrew S. Day, Richard B. Gearry
Abstract not available
-
Clinical practices and adherence to guidelines for eosinophilic esophagitis: A European survey Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-29 Andrea Sorge, Marina Coletta, Luca Elli, Albert J. Bredenoord
Background We aimed to assess the clinical practices and adherence to guidelines for adult Eosinophilic Esophagitis (EoE) patients in Europe. Methods A cross-sectional web survey containing 23 questions was distributed to members of the European Consortium for Eosinophilic Diseases of the Gastrointestinal Tract (EUREOS) and the Italian Association of Hospital Gastroenterologists and digestive endoscopists
-
Gastric adenocarcinoma of fundic gland type Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-29 Ding Zhang, Wei Liu, Zu-Jiang Yu
Abstract not available
-
Artificial intelligence for liver diseases: The urgency of collaboration Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-29 Manuela Cesaretti, Alessandro Izzo, Orestes Mavrothalassitis, Roberta Anna Pellegrino
Abstract not available
-
Overexpression of NDRG1 leads to poor prognosis in hepatocellular carcinoma through mediating immune infiltration and EMT Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-29 Xiao Wang, Ran Sun, Na Che, Danfang Zhang, Yanlei Li, Nan Zhao
Background NDRG1, the first member of the NDRG family, is a multifunctional protein associated with carcinogenesis. Its function in human cancer is currently poorly understood. The aim of this study was to explore the importance of NDRG1 in tumor immune cell infiltration and epithelial–mesenchymal transition (EMT) in hepatocellular carcinoma. Methods NDRG1 expression in various cancers was analyzed
-
ABCA8: A potential therapeutic target in the treatment of colorectal cancer? Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-27 Dian-Bo Dong, Hong-Jin Shao
None
-
Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-28 Jian Tang, Qing Li, Zhaopeng Huang, Lishuo Shi, Qin Guo, Miao Li, Xiang Gao, Kang Chao
Background and Aims Re-induction optimization of ustekinumab is effective in Crohn's disease (CD) patients who experienced a loss of response (LOR) to ustekinumab. However, whether continuous multiple intravenous optimization is better than single dose re-induction remains unknown. We aimed to compare effectiveness of two strategies in CD patients with LOR to ustekinumab. Methods We retrospectively
-
Hepatofugal portal flow is highly predictive of acute-on-chronic liver failure: A new hemodynamic patho-physiological hypothesis Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-27 Bevilacqua Michele, De Marco Leonardo, Stupia Roberta, Cattazzo Filippo, Zoncapé Mirko, Paon Veronica, Ieluzzi Donatella, Dalbeni Andrea, Sacerdoti David
Background and aims Acute-on-chronic liver failure (ACLF) is a severe complication of advanced liver disease. A significant number of ACLF patients have not clear precipitating factors. The aim of the study was to investigate the role of alterations in porto-hepatic hemodynamics, especially non-forward portal flow (NFPF), in ACLF and liver-related mortality. Methods 233 cirrhotic patients were included
-
Do glucagon-like peptide-1 based therapies alter the risk of late-onset inflammatory bowel disease? Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-27 Heidi Søgaard Christensen, Diana Vincens Andersen, Tine Jess, Kristine Højgaard Allin
Abstract not available
-
Mismatch repair deficiency in multifocal gastric epithelial neoplasia and non-dysplastic glands: Harbinger of Lynch syndrome in an autoimmune gastritis patient Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-22 Alessandro Vanoli, Marco Vincenzo Lenti, Fabio Sirchia, Antonio Di Sabatino
Abstract not available
-
Full Title Page /Editorial Board Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-25
Abstract not available
-
An artificial intelligence system for chronic atrophic gastritis diagnosis and risk stratification under white light endoscopy Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-20 Xiao Tao, Yijie Zhu, Zehua Dong, Li Huang, Renduo Shang, Hongliu Du, Junxiao Wang, Xiaoquan Zeng, Wen Wang, Jiamin Wang, Yanxia Li, Yunchao Deng, Lianlian Wu, Honggang Yu
Background and Aims The diagnosis and stratification of gastric atrophy (GA) predict patients’ gastric cancer progression risk and determine endoscopy surveillance interval. We aimed to construct an artificial intelligence (AI) system for GA endoscopic identification and risk stratification based on the Kimura-Takemoto classification. Methods We constructed the system using two trained models and verified
-
OC.11.6 CONSTIPATION: A PDTA PROPOSAL BETWEEN HOSPITAL AND TERRITORY Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-21 L. D'Alba, E. Battaglia, M.C. Neri
-
OC.11.5 SMAD7 SUSTAINS THE METABOLIC REPROGRAMMING OF COLORECTAL CARCINOMA CELLS Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-21 M. Colella, C. Maresca, A. Di Grazia, D. Di Fusco, E. Franze, T. Pacifico, F. Laudisi, C. Stolfi, I. Monteleone, G. Monteleone
-
OC.11.4 ITALIAN SOCIETY FOR DIGESTIVE DISEASES ACCREDITATION PROGRAM DURING COVID-19 PANDEMIC: RESULTS IN REMOTE REACCREDITATION IN 15 CENTRES Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-21 G. Spinzi, P. Da Massa Carrara, V. Boarino, P. Brosolo, T. Iannone, A. Merighi, M. Labardi, A. Milano, G. Rando, M. Capelli
-
Prevalence and features of chronic nonbacterial osteomyelitis in a cohort of children with inflammatory bowel diseases Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-16 Luca Scarallo, Daniela Knafelz, Serena Arrigo, Enrico Felici, Paolo Lionetti, Edoardo Marrani, Gabriele Simonini, Patrizia Alvisi, Matteo Bramuzzo, Claudio Romano
Abstract not available
-
Trends in liver transplantation for primary sclerosing cholangitis Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-16 Maria Cristina Morelli, Martina Gambato, Silvia Martini, Paola Carrai, Pierluigi Toniutto, Valerio Giannelli, Francesca Donato, Ilaria Lenci, Luisa Pasulo, Chiara Mazzarelli, Alberto Ferrarese, Maria Rendina, Antonio Grieco, Alfonso Galeota Lanza, Gianluca Svegliati Baroni, Nicola De Maria, Simona Marenco, Laura Mameli, Francesca Romana Ponziani, Giovanni Vitale, Clara Dibenedetto
Background Primary sclerosing cholangitis is a cholestatic disease with a low prevalence in Italy. Indications for liver transplantation and the time of listing are not stated. Aim We performed a national survey to investigate the listing criteria, comorbidities, and outcomes. Methods In April 2022, we surveyed liver transplantation in primary sclerosing cholangitis nationwide for the last 15 years
-
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-16 Emmanuelle Samalin, Thibault Mazard, Eric Assenat, Magali Rouyer, Christelle de la Fouchardière, Rosine Guimbaud, Denis Smith, Fabienne Portales, Marc Ychou, Antoine Adenis, Catherine Fiess, Evelyne Lopez-Crapez, Simon Thezenas
Background Triplet chemotherapy plus cetuximab showed promising results in phase II trials in unsystematically selected RAS population. We evaluated FOLFIRINOX+cetuximab efficacy as first-line treatment in extended RAS wild-type metastatic colorectal cancer (mCRC) patients. Methods We retrospectively analyzed patients treated with FOLFIRINOX+cetuximab, using data from clinical trials and real-life
-
Peri-onset non-steroidal anti-inflammatory drugs use and organ failure in acute pancreatitis: A multicenter retrospective analysis Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-15 Hsing-Chien Wu, Kuo-Liong Chien, Jing-Rong Jhuang, Yen-Yun Yang, Wei-Chih Liao
Background Organ failure (OF) of acute pancreatitis (AP) significantly contributes to AP-related mortality. Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced complications of AP. Aims We aimed to investigate whether NSAIDs ameliorates SIRS and OF in patients with AP. Methods Eligible patients with AP were retrospectively identified in 4 hospitals between January 2015
-
Biomarkers of fibrosis and portal hypertension in Fontan-associated liver disease in children and adults Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-13 Chaowapong Jarasvaraparn, Jessica Thoe, Andrew Rodenbarger, Howard Masuoka, R. Mark Payne, Larry Wayne Markham, Jean P. Molleston
Background Fontan-associated liver disease (FALD) refers to structural and functional changes of the liver caused by the physiology of the Fontan palliation. Currently, liver biopsy is the gold standard to assess liver fibrosis of FALD. Aim Investigate biomarkers correlating with severity of liver biopsy fibrosis in FALD. Methods A retrospective study of post-Fontan patients ≥ 10 years of age who underwent
-
Endoscopic management of gastric, duodenal and rectal NETs: Position paper from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Society of Gastroenterology (SIGE), Italian Society of Digestive Endoscopy (SIED) Dig. Liver Dis. (IF 4.5) Pub Date : 2024-01-11 Francesco Panzuto, Maria Caterina Parodi, Gianluca Esposito, Sara Massironi, Alberto Fantin, Renato Cannizzaro, Massimo Milione, Claudio Giovanni De Angelis, Bruno Annibale
The present paper reflects the position of the Italian Association for Neuroendocrine Tumors (Itanet), the Italian Society of Gastroenterology (SIGE), and the Italian Society of Digestive Endoscopy (SIED) regarding the management of patients affected by gastric, duodenal, and rectal neuroendocrine neoplasms (NENs) amenable to endoscopic treatment. The key questions discussed in this paper are summarized